ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 5, 2017--
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology
company focused on developing and commercializing products addressing
degenerative diseases, today announced that Jim Knight, Senior Vice
President, Head of Corporate Development, will present at the LD Micro
San Francisco Summit at the Sir Francis Drake Hotel in San Francisco.
Mr. Knight will provide an overview of the Company in his presentation
on Tuesday, September 5, 2017 at 2:00 pm PT/5:00 pm ET.
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company focused on developing
and commercializing products addressing degenerative diseases. Its
clinical programs are based on two platform technologies: pluripotent
cells and cell/drug delivery. The foundation of BioTime’s core
therapeutic technology platform is pluripotent cells that are capable of
becoming any of the cell types in the human body. The foundation of the
Company’s cell delivery platform is its HyStem® cell and drug delivery
matrix technology. The Company’s current clinical programs are targeting
three primary sectors, aesthetics, ophthalmology and cell/drug delivery.
BioTime also has significant equity holdings in two publicly traded
companies, Asterias Biotherapeutics, Inc. and OncoCyte Corporation.
BioTime common stock is traded on the NYSE American and TASE under the
symbol BTX. For more information, please visit www.biotimeinc.com or
connect with the company on Twitter, LinkedIn, Facebook, YouTube,
To receive ongoing BioTime corporate communications, please click on the
following link to join the Company’s email alert list: http://news.biotimeinc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170905005610/en/
Source: BioTime, Inc.
David Nakasone, 510-871-4188
JQA Partners, Inc.
Jules Abraham, 917-885-7378